Compare FRST & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRST | PGEN |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 342.4M | 1.4B |
| IPO Year | 2006 | 2013 |
| Metric | FRST | PGEN |
|---|---|---|
| Price | $14.33 | $4.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 241.2K | ★ 3.0M |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | ★ 477.27 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | N/A | $1,115.92 |
| Revenue Next Year | $9.63 | $81.04 |
| P/E Ratio | $47.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.25 | $1.28 |
| 52 Week High | $14.97 | $5.47 |
| Indicator | FRST | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 55.01 | 53.93 |
| Support Level | $13.71 | $3.97 |
| Resistance Level | $14.45 | $4.40 |
| Average True Range (ATR) | 0.28 | 0.25 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 55.09 | 36.41 |
Primis Financial Corp is the bank holding company for Primis Bank, providing financial services to individuals and small and medium-sized businesses. Primis Bank offers a wide range of commercial banking services, It focuses on making loans secured mainly by commercial real estate and other types of secured and unsecured commercial loans to small and medium-sized businesses in several industries, as well as loans to individuals for a variety of purposes. The company has two reportable segments: Primis Bank. This segment specializes in providing financing services to businesses in various industries along with consumer and residential loans to individuals. Primis Mortgage. This segment specializes in originating mortgages in a majority of the U.S. The revenue is from Primis Bank.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.